It’s been five years since Mann told FORBES that Afrezza would be one of the “most valuable products ever.” But he still insists he wouldn’t sell Mannkind for $25 a share.
Al Mann instructed his staff to keep silent about a year ago. This was stated on one of the blogs referencing internal discussions. Since then this blog is no where to be found, have searched every historical sites visited and it no longer exists. Furthermore, the huge awards extended to staff is for their reward for following orders.
Stock price is a reflection of confidence on it's product.
Currently, would you put in your body a product that lost over 60% of its value?
Management ... sit back and relax ... there is no urgency.
I would not and would not buy.
Right now Afrezza is a failed drug.
Heck no. You want these guys to sell something?
Didn't you say they are incapable of selling heat to Eskimo?
I say they are extremely efficient in their work.
Only advertisements need to hit TV and magazines.
Doctors need to be introduced to Afrezza.
Afrezza press releases need to be positive.
And market will POP the PPS.
and you get the current PPS.
is there a creative accounting we are not aware of?
Your examples only concentrate on bankruptcies.
There are other buyouts that favor long investors.
Facebook received many lucrative offers and all were turned down.
Kevin, you are the king of Afrezza.
Worth reading post and I will accept $17.
He has no respect from his shareholders, so he is trying to improve things.